她再也控制住自己情感，边哭边喊着妈妈。
小公举深夜开启17年虐狗第一弹，宣布昆凌怀二胎。
声明：本文由入驻搜狐公众平台的作者撰写，除搜狐官方账号外，观点仅代表作者本人，不代表搜狐立场。
　　TAF(tenofovir alafenamide fumarate，替诺福韦艾拉酚胺富马酸)是一种新型核苷类逆转录酶抑制剂(NRTI)，该药是吉利德已上市药物Viread(替诺福韦酯，TDF)的升级改良版。
　　据吉利德发布的声明，此次NDA的提交，是在巴塞罗那玛利亚医院和香港中文大学对基于2个III期研究(Study 108和Study 110)的48周数据，均获得成功。这也达到了研究的终点。研究数据证明了TAF相对于Viread(TDF)的非劣效性。此外TAF 进入细胞，包括HIV感染的细胞，与Viread相比 TAF更有效，即使使用很低的剂量 ,TAF在肾脏和骨骼的安全性方面也更好。当然，Viread(TDF)替诺福韦也是一种新型NRTI药物，目前被广泛用于HIV(艾滋)和HBV(乙肝)的治疗。此药物也通常认为是安全的和有良好的药物耐受性，但长期服用药物治疗，会导致少量骨质流失，对于易感人群会造成肾脏问题。
　　这种核苷/核苷酸类似物，像Viread替诺福韦是能有效抑制乙肝病毒复制的，但通常不能治愈乙肝表面抗原(HBsAg)损失和anti-HBs抗体的发展，所以乙肝和艾滋病，往往都需要长期治疗。
　　伊顿健康了解到，作为替诺福韦德升级改良版，TAF是一个新的前药配方，只用TDF1/10的剂量就可以在肝细胞和CDT细胞中生产出高水平的活性药物（替诺福韦二磷酸），这也就意味着在血液中浓度会更低，会有更少的药物暴露在肾脏、骨骼和其他器官组织里，有非常高的抗病毒效果。
　　2015年11月，美国食品药监局（FDA)批准 Genvoya，为第一个含有TAF的组合药片作为治疗12岁以上的儿童和成人HIV-1感染的指定用药。另外两个含有TAF的共制剂Odefsey和 Descovy也已经被批准。此外TAF也正在作为一个独立的治疗乙型肝炎的药物治疗。
　　对于一些年长和产生并发症的病人，TAF是一个好的选择，同时TAF 对于艾滋病毒治疗的优势已被证明。如果患者需要长期治疗，TAF 也是更安全的选择。
　　作为乙肝新药TAF（Tenofovir alafenamide）将取代替诺福韦，相信TAF的上市将对于中国患者来说是久违的好消息
　　中国乙肝患者占全球1/3
　　据统计，在全球范围内，有多达3.5―4亿乙肝患者 ，而中国13亿人口中就占去一亿的慢性乙型肝炎病毒(HBV)感染者，占全球乙肝携带者的1/3，该病导致的肝硬化是全球80%原发性肝癌的直接病因。而我国乙肝发病率还在持续上升。
　　乙型肝炎是一种通过接触感染者的血液或其它体液传播的损害肝脏的病毒感染，可造成急性或慢性疾病，甚至可能威胁生命，伊顿健康咨询提醒大家，注意乙肝的传播传染途径，加强饮食管理，保持卫生，防止感染，如有发现一定要早治疗。
　　伊顿健康称“慢性乙肝感染是危及生命的疾病，可导致肝衰竭，肝癌和死亡。数以百万计人饱受该疾患困苦，它仍然是全世界显著的健康问题之一。TAF的III期结果推动了乙肝治疗，不仅能提供Viread类似的功效，并具有改善骨骼和肾脏安全性参数的特点。希望此药上市的时候伊顿健康可以为患者找到廉价的新药TAF.
　　伊顿健康坚信很快，另外的RNA干扰疗法能有望功能性治愈乙肝！
欢迎举报抄袭、转载、暴力色情及含有欺诈和虚假信息的不良文章。
请先登录再操作
请先登录再操作
微信扫一扫分享至朋友圈
搜狐公众平台官方账号
生活时尚&搭配博主 /生活时尚自媒体 /时尚类书籍作者
搜狐网教育频道官方账号
全球最大华文占星网站-专业研究星座命理及测算服务机构
顿健康咨询有限公司成立于2016年8月，总部位于江苏常州，...
主演：黄晓明/陈乔恩/乔任梁/谢君豪/吕佳容/戚迹
主演：陈晓/陈妍希/张馨予/杨明娜/毛晓彤/孙耀琦
主演：陈键锋/李依晓/张迪/郑亦桐/张明明/何彦霓
主演：尚格?云顿/乔?弗拉尼甘/Bianca Bree
主演：艾斯?库珀/ 查宁?塔图姆/ 乔纳?希尔
baby14岁写真曝光
李冰冰向成龙撒娇争宠
李湘遭闺蜜曝光旧爱
美女模特教老板走秀
曝搬砖男神奇葩择偶观
柳岩被迫成赚钱工具
大屁小P虐心恋
匆匆那年大结局
乔杉遭粉丝骚扰
男闺蜜的尴尬初夜
客服热线：86-10-
客服邮箱：广生堂【300436】<strong style='color:#.67　-0.40　-0.83%
咨询热线：400-887-5001　|　　|　
关注福建广生堂的微信
方法1：查找“福建广生堂药业”
方法2：用微信扫描二维码：
官方微信　|　
乙肝新药：TAF(替诺福韦艾拉酚胺)相比TDF(替诺福韦)更强
发布：　|　来源：医谷　|　浏览：313
终于批准了， Gilead 一年前就放出了风声，这个药物的临床效果不错， 虽然不及治疗丙肝的Harvoni 那么革命行的效果， 但对于乙肝患者而言这也是最新的突破了。 11月10号，Gilead Sciences公司宣布，美国FDA已经批准其新药产品Vemlidy(tenofovir alafenamide，TAF)25mg，每日一次治疗伴有代偿性肝病的慢性乙型肝炎病毒(HBV)感染。
Vemlidy是一种创新型、靶向性、tenofovir前药，与Gilead的先前产品 300mg的Viread (tenofovir disoproxil fumarate, TDF)相比， 只需要少于十分之一的剂量就可达到类同的抗病毒功效。
临床数据显示，与Viread相比，Vemlidy具有更大的血浆稳定性而且可更有效地将tenofovir递送到肝细胞，所以可以使用更低的给药剂量，导致血液中富含更少的tenofovir。因为上述原因，与Viread相比，Vemlidy有效改善了针对肾脏和骨骼的安全性参数。
TDF与TAF分子式对比，左为TDF，右为TAF，来自网络
Vemlidy在两个国际型3期临床试验(研究108和研究110)试验中，获得了长达48周的数据支持。共有1298名初治和有过治疗的慢性HBV感染成人患者参与临床试验。研究108使用Vemlidy或Viread随机化治疗了425例HBeAg阴性患者，研究110使用Vemlidy或Viread随机化治疗了873名HBeAg阳性患者。
两个研究都达到了它们的主要临床研究终点：在治疗第48周时，基于血浆HBV DNA水平低于29 IU/mL的慢性乙型肝炎患者的百分比这一指标中，Vemlidy显示出了相对Viread的非劣效性。
另外，Vemlidy和Viread在两项研究中患者的耐受性均表现良好，由于不良反应而中止治疗的分别为1.0%和1.2%。两个研究中最常见的不良反应主要包括头痛，腹痛，疲劳，咳嗽，恶心和背痛，并且不良反应的发生率在接受Vemlidy或Viread治疗的患者基本相同。
Gilead Sciences公司总裁兼首席执行官 John Milligan 博士说：“自20世纪90年代中期以来，吉利德一直致力于改善和简化慢性乙型肝炎患者的治疗。Vemlidy是在近十年内被批准用于治疗这种疾病(慢乙肝)的第一个药物，我们很高兴能提供一个新的有效的治疗选择，以帮助促进患者的长期健康护理。”
不过值得注意的是Vemlidy在其产品标签中有一个黑框警告，提醒注意治疗后严重急性加重性乙肝，伴有脂肪变性的严重肝肿大，以及乳酸性酸中毒风险。
参考英文原文
《U.S. Food and Drug Administration Approves Gilead’s Vemlidy(R) (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection》
Gilead Sciences, whose hepatitis C dynasty has been slipping, has won approval for its next-gen hepatitis B treatment.
The Foster City, CA-based drugmaker said Thursday that the FDA had approved Vemlidy, a once-daily treatment for adults with chronic hepatitis B virus (HBV) with compensated liver disease. The drug, however, comes with a black-box warning for risks.
Gilead ($GILD) already has a hep B treatment, Viread, but said today that the new drug can be given at one-tenth the dose of Viread and so has better renal and bone laboratory safety parameters than its predecessor.
Dr. Calvin Pan, a clinical professor of medicine at NYU Langone Medical Center and an investigator in the Vemlidy clinical trials, said the improved renal and bone safety parameters were an important development for the 2.2 million people in the U.S. suffering from the life-threatening disease.
approval comes at a time when Gilead’s one-time powerhouse hep C treatments Sovaldi and Harvoni have fallen victim to competition and payer discounting, with sales plummeting 31% for the last quarter. The results missed consensus estimates by 3%, even with help from the recent rollout of Epclusa, a regimen that spans all hep C genotypes.
Investors are still looking for Gilead to buy something significant that can pull it out of the dive, as it did when it acquired the asset that turned into Sovaldi and Harvoni. It was rumored to be looking at cancer biotech Medivation, but blocked folks from the deal with a $14 billion bid.
CEO John Milligan told investors that the company is “currently very, very active” in looking for M&A deals but will only “do things when they make sense for us and not before then.”
Editor's Note: The story was updated with information about the EU's CHMP recommending Vemlidy.
地址：福建省福州市鼓楼区软件大道89号软件园B区10号楼B座
中华人民共和国互联网药品信息服务资格证书编号：(闽)-非经营性-
Copyright◎2015 福建广生堂药业股份有限公司名称为：9-[(R)-2-[[双[[（异丙氧基羰基）氧基]甲氧基]氧膦基]甲氧基]-丙基]腺嘌呤富马酸盐（1∶1）。意见建议：是一种新型核苷酸类逆转录酶抑制剂。可有效对抗多种病毒，用于治疗病毒感染性疾病。这款进口药品对治疗艾滋病和乙肝两大顽疾的功效已获公认，但其在国内却并未正式上市，而是通过网络、代购等非正规渠道销售，因此被认定为假药。2008年，替诺福韦获得针对艾滋病治疗的批文，但其作为治疗乙肝的药品仍在临床试验中，尚未获准在国内销售。 2013年8月，国家食品药品监督管理总局公布《严重违法发布假药信息网站名单》，替诺福韦涉及其中。
您的举报已经提交成功，我们将尽快处理，谢谢！
三者一起服用主要治疗病毒感染性疾病如肝炎或者HIV等。这个最好在晚间服用比较好的
谢谢信任。因为时间久了，您上次咨询的内容我不记得了。但您本次提供的信息是比较完整的。有以下建议，请参考：1）干扰素无应答通常提示您的抗乙肝病毒的特异性免疫不佳，...
乙肝疫苗分三次注射，一般三个后能产生抗体，你可以查个乙肝五项就知道有没有抗体了。当然不是每个人注射疫苗后都能产生抗体，这和个人的免疫系统有关，多数人注射疫苗后能...
答: 这样应该是
大家还关注重磅！吉列德替诺福韦（TAF）正式获FDA批准上市用于慢乙肝治疗
重磅！吉列德替诺福韦（TAF）正式获FDA批准上市用于慢乙肝治疗
据吉利德科学公司(Nasdaq: GILD)官方网站公布消息，公司用于慢乙肝治疗的新药替诺福韦（替诺福韦艾拉酚胺，TAF，商品名Vemlidy(R)，25mg，每日一次）于本月10日获得美国食品和药物管理局
据吉利德科学公司(Nasdaq: GILD)官方网站公布消息，公司用于慢乙肝治疗的新药替诺福韦（替诺福韦艾拉酚胺，TAF，商品名Vemlidy&，25mg，每日一次）于本月10日获得美国食品和药物管理局（FDA）批准用于成人慢乙肝而没有失代偿期肝病患者的治疗。
Vemlidy 在其产品标签中有一个黑框警告，是关于经治疗后严重急性加重的慢乙肝有脂肪变性出现乳酸性酸中毒/严重肝肿大风险的。
Vemlidy是替诺福韦的新型靶向前药，已证明仅为 Gilead 的 300mg Viread&（替诺福韦地索普西延胡索酸盐，TDF） 十分之一剂量便可获得相似的抗病毒效用。数据显示 Vemlidy具有更大的血浆稳定性和更有效地将替诺福韦递送给肝细胞，所以用药剂量可以更低，从而可以使血液中替诺福韦浓度更低。因此，与Viread& 相比，Vemlidy 改善了肾和骨实验室的安全参数。
&慢性乙型肝炎是一种威胁生命的疾病，在美国影响高达220万人，& 纽约大学朗根医学中心临床医学教授和 Vemlidy 临床试验调查员 Calvin Pan 博士说 &临床试验表明，与Viread相比，Vemlidy能显著有效改善肾脏和骨骼安全性参数，意味着对患这种疾病的患者来说是一种改善。&
Vemlidy的批准是基于来自两个国际3期临床研究（研究108和110）48周数的据支持下获得的，研究是在1298名未经治和经治的成人慢乙肝患者中进行的。108研究随机给予425例HBeAg阴性慢乙肝患者Vemlidy或Viread进行治疗，110研究随机的给予873 例 HBeAg 阳性慢乙肝患者Vemlidy或Viread治疗。经过48周的治疗后，两个研究都达到了他们的首要研究终点，即在经过48周的治疗后，基于慢性乙型肝炎患者在48周治疗时血浆HBV DNA水平低于29 IU / mL的百分比，Vemlidy 非劣效于Viread 。
在两个研究的综合分析中，与使用Viread治疗的那些患者相比，接受Vemlidy治疗的患者某些骨和肾实验室参数获得改善。Vemlidy 组中患者血清丙氨酸氨基转移酶（ALT）水平正常化速率也更高。
Vemlidy和Viread在两项研究中患者的耐受性均表现良好，由于不良事件而中止治疗的分别为1％和1.2％。两个研究中最常见的不良事件包括头痛，腹痛，疲劳，咳嗽，恶心和背痛，并且在接受 Vemlidy 或 Viread 治疗的患者发生率是相似的。
吉利德科学公司总裁兼首席执行官 John Milligan 博士说：&自20世纪90年代中期以来，吉利德一直致力于改善和简化慢性乙型肝炎患者的治疗。Vemlidy是在近十年内被批准用于治疗这种疾病（慢乙肝）的第一个药物，我们很高兴能提供一个新的有效的治疗选择，以帮助促进患者的长期健康护理。&
U.S. Food and Drug Administration Approves Gilead&s Vemlidy& (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
-- Vemlidy is a Once-Daily Treatment that Demonstrated Similar Efficacy with Improved Renal and Bone Laboratory Safety Parameters Compared to Viread --
FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy& (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.
Vemlidy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. See below for important safety information.
Vemlidy is a novel, targeted prodrug of tenofovir that has demonstrated antiviral efficacy similar to and at a dose less than one-tenth that of Gilead&s Viread& (tenofovir disoproxil fumarate, TDF) 300mg. Data show that because Vemlidy has greater plasma stability and more efficiently delivers tenofovir to hepatocytes compared to Viread, it can be given at a lower dose, resulting in less tenofovir in the bloodstream. As a result, Vemlidy improved renal and bone laboratory safety parameters compared to Viread.
&Chronic hepatitis B is a life-threatening illness that affects up to 2.2 million people in the U.S.,& said Calvin Pan, MD, Clinical Professor of Medicine, NYU Langone Medical Center, and investigator in the Vemlidy clinical trials. &Clinical trials demonstrated Vemlidy is efficacious with improved renal and bone safety parameters compared to Viread, representing an important development for people living with this chronic disease.&
Photos and multimedia gallery available at .
Vemlidy&s approval is supported by 48-week data from two international Phase 3 studies (Studies 108 and 110) among 1,298 treatment-na&ve and treatment-experienced adult patients with chronic HBV infection. Study 108 randomized and treated 425 HBeAg-negative patients with either Vemlidy or Viread, and Study 110 randomized and treated 873 HBeAg-positive patients with either Vemlidy or Viread. Both studies met their primary endpoint of non-inferiority to Viread based on the percentage of patients with chronic hepatitis B with plasma HBV DNA levels below 29 IU/mL at 48 weeks of therapy.
In an integrated analysis of both studies, patients receiving Vemlidy demonstrated improvements in certain bone and renal laboratory parameters compared to those treated with Viread. Patients in the Vemlidy arm also experienced numerically higher rates of normalization of blood serum alanine aminotransferase (ALT) levels.
Vemlidy and Viread were generally well-tolerated by patients in both studies and discontinuations due to adverse events were 1% and 1.2%, respectively. The most commonly reported adverse events in both studies included headache, abdominal pain, fatigue, cough, nausea and back pain and occurred at similar rates in patients receiving either Vemlidy or Viread.
&Since the mid-1990s, Gilead has been working to improve and simplify care for people living with chronic hepatitis B,& said John Milligan, Ph.D., President and Chief Executive Officer of Gilead Sciences. &Vemlidy is the first medication approved to treat this disease in nearly a decade, and we are excited to offer a new, effective option to help advance long-term care for patients.&
了解更多内容敬请下载手机APP。
本网站所有注明“来源：艾兰博曼医学网”的文字、图片和音视频资料，版权均归艾兰博曼医学网所有，欢迎转载，但请务必注明出处“艾兰博曼医学网”，否则将追究法律责任。本网所有注明来源为其他媒体的内容仅出于传递更多信息之目的，版权归原作者所有，不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。本站已经通过实名认证，所有内容由李在村大夫本人发表
当前位置：
& 大夫个人网站
& 文章详情
新的可以替换 替诺福韦的药物
& & TAF所需剂量很小，只是TDF的1/12~1/30,而细胞内浓度高4倍，血浆内浓度低90%。血浆内浓度低，意味着副反应小。临床试验也证实了疗效不低于TDF，而对肾脏和骨的毒性却小。美中不足的是，这个药不是作为单药开发的，而是作为四合一药物的一种成分而开发的。其实，TAF的开发商10年前就能把这个药物研制出来，但那样的话不是砸自己的TDF的牌子吗？眼看TDF的知识产权保护期要过了，公司适时推出换代产品TAF。可见，万恶的资本家不会把患者利益放第一位的，股东的利益永远第一。哎，也许这本没有错。By Simon CollinsFrom&Of several new pipeline compounds with new data at CROI 2015, the most advanced in development was tenofovir alafenomide (TAF), the new version of tenofovir.TAF is notable for a low milligram dose (10 mg or 25 mg) that achieves intracellular drug levels that are 4-fold higher and plasma levels that are 90% lower, than with 300 mg of tenofovir disoproxil fumarate (TDF).In the first TAF oral presentation, David Wohl from University of North Carolina presented results from a prespecified combined analysis of two randomised TAF studies (0104 and 0111).1AdvertisementThe development programme for TAF is notable for prioritising coformulations rather than the individual drug and these studies compared two fixed-dose combinations (FDCs): elvitegravir/cobicistat/FTC/TAF (n=866) vs elvitegravir/cobicistat/FTC/TDF (Stribild), (n=867), starting with similar baseline characteristics and finding similar results. Dosing for each FDC is one pill, once-daily.Both studies were randomised, double-blind, placebo controlled non-inferiority studies (lower margin of 95% CI = 12%), with primary endpoints of viral suppression to&50 copies/mL at week 48.Baseline characteristics were closely matched between arms. Median age was 44 85% were men, 15% 25% had black or African descent and 19% were Hispanic/Latino. The median CD4 and viral load were 405 cells/mm3 and 4.58 log copies/mL, with 12%&200 mm3=&& and=&&&100,000 copies/mL.At week 48, viral load was&50 copies/mL in 92% (TAF) vs 90% (TDF), difference +2.0% (95% CI: 0.7% to +4.7%). Approximately 5% (n=45) and 8% (n=71) discontinued treatment during the study, leaving 821 vs 796 participants in the primary analysis. When stratified by baseline viral load below/above 100,000 copies/mL results were 94% vs 91% (above) and 87% vs 89% (below), in the TAF vs TDF arms respectively. CD4 increases were also similar when stratified by baseline CD4 below (86% vs 89%) and above (86% vs 89%) 200 cells/mm3.Efficacy results were not affected by age (above/below 50 years) or sex, but were slightly lower in both arms in black vs non-black participants: 88% vs 83% (below 50) and 94% vs 93% (above 50).Increases in CD4 count were significantly higher with TAF: +211 vs +181 cells/mm3, p=0.024.Of 4% of participants in each arm with viral failure, 1.8% (n=16) vs 2.2% (n=19) had resistance testing, with similare low rates of resistance to either NRTI (n=7 vs 5) or NNRTIs (n=5 vs 3).The pattern of similar results continued for side effects: approximately 45% were drug-related but only 1% were grade 3/4, and 0.3% were serious -- with discontinuations by only 0.9% (n=8) and 1.5% (n=15), in the TAF vs TDF arms, respectively. Five deaths were attibuted to stroke (1), alcohol intoxication (1), alcohol and drug intoxication (1) and myocardial infarction (2).Common side effects (18% diarrhoea, 16% nausea, 13% headache, 12% upper respiratory tract infection, etc) were mild, with no cases of proximal renal tubulopathy in either study.With marginal differences between FDCs for efficacy endpoints, the interest shifted to bone, renal and lipid results presented the following day by Paul Sax from Brigham and Women&#39;s Hospital and Harvard Medical School, Boston.In this analysis, renal differences included less reduction from baseline in eGFR (Cockroft-Gault) in the combined TAF compared to the TDF groups: median -6.6 vs -11.2 mL/ p&0.001. The four renal discontinuations were all in the TDF groups: renal failure (2), decreased GFR (1), nephropathy (1). Significant median percentage changes from baseline of four sub-clinical markers of proteinuria all favoured TAF: protein -3% vs +20%, albumin -3% vs +7%, retinol binding protein +9 % vs +51% and beta2 microglobumin -32% vs +24%; all p & 0.001.Mean percentage changes in bone measured by DEXA also favoured TAF vs TDF: at spine -1.30 % vs -2.86 % and hip -0.66 % vs -2.95 %; both p&0.001.& p=&&&Finally, median changes from baseline in lipid parameters (mg/dL) all increased more in the TAF vs TDF arms: TC +29 vs +14; LDL +14 vs +5; HDL +7 vs +4; (all p&0.001); and TG +19 vs +8, p=0.027. However, there were no significant differences between arms in change from baseline of the TC:HDL ratio (p=0.84) or in the use of lipid lowering drugs (p=0.42).A poster at CROI provided preliminary renal, bone and lipid data on use of TAF in patients with moderate-mild (stage 3-2) renal impairment, defined as eGFR 30-69 mL/min.3This was 48-week data from a 96 week Phase 3 study in 242 stable patients on treatment (with or without TDF) with an undetectable viral load (&50 copies/mL) for at least six months, who were switched to the single tablet combination of elvitegravir/cobicistat/FTC/TAF (E/C/T/TAF). The primary endpoint was the change in eGFR from baseline to week 24. Hepatitis B/C were exclusion criteria. Patients were stratified by eGFR & 50 mL/min (n=59) and &50 mL/min (n=162).Baseline characteristics included median age 58 (IQR: 52, 65) years, 21% women, 18% African descent, median CD4 632 cells/mm3. Differences in the&50 vs=&&&50 groups included re-switch TDF use in 58% vs 69%, hypertension in 50% vs 34%, median eGFR 43 vs 60 mL/min/1.73 m2 (57 vs 77 when adjusted for age and sex), clinically significant proteinuria 58% vs 35% and clinically significant albuminuria in 64% vs 32%, respectively. Boosted PI was used by 44% of the overall group (breakdown by TDF use not provided).At week 48, 222/242 (92%) remained virologically suppressed (&50 copies/mL), with data not available for 22 people (7%). There were seven discontinuations due to side effects: two for renal failure (eGFR decline), diarrhoea, choking, fatigue, joint swelling, sleep disorder and bladder cancer.At week 24, median (IQR) changes in eGRF (Cockroft-Gault) was -0.4 (-4.8, +4.5) and adjusted eGFR (CKD-EPI cystatin C) was +3.8 (-4.8, +11.2) mL/min/1.73 m2. Changes by baseline stratification appeared similar. Actual eGFR measured by iohexol clearance in a sub group of 32 patients remained similar at baseline and at weeks 2, 4, 8, and 24. Changes in proteinuria and albuminuria remained stable or improved for nearly all patients, with only 5%, 2% and 0% worsening in participants with baseline grade 0, 1 and 2, respectively. There were no cases of proximal renal tubulopathy or Fanconi syndrome.Median (IQR) changes in bone mineral density (BMD) at week 48 increased by 1.9% (-0.3, +4.3) n the spine and 0.9% (-0.3, +2.7) in the hip (both p&0.001), although BMD was reduced in more than 25% of patients at both regions.Changes in lipids (mg/dL) from baseline to week 48 showed differences when stratified by prior TDF use: TC +19 vs -11; LDL +7 vs -4; HDL +1 vs -4; and TG +12 vs -1; with changes in TC:HDL ratio of +0.3 vs +0.2, all in the prior-TDF vs no-TDF groups respectively.TAF is probably a better drug than TDF, and the sub-clinical markers may have advantages. However, these were not sufficiently important for patient care for Gilead to prioritise it&#39;s development.Gilead had in vitro data on the potential benefits of TAF (formerly GS-7340) in 2001 and held back on development for over a decade before presenting Phase 1 data at CROI in 2011.4,5Unless stated otherwise, all references are to the Programme and Abstracts of the 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015), 23-26 February 2015, Seattle.Wohl D et al.&. 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015), 23-26 February 2015, Seattle. Oral late breaker abstract 113LB.Sax P et al.&. 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015), 23-26 February 2015, Seattle. Oral late breaker abstract 143LB.Pozniak A et al.&. 2015 Conference on Retroviruses and Opportunistic Infections (CROI 2015), 23-26 February 2015, Seattle. Poster abstract 795.Eisenberg EJ, He GX, Lee WA.&.&Nucleosides Nucleotides Nucleic Acids. 2001 Apr-J20(4-7):1091-8. doi: 10.1081/NCN-.Markowitz M, Zolopa A, Ruane P, et al. GS-7340 demonstrates greater declines in HIV-1 RNA than TDF during 14 days of monotherapy in HIV-1-infected subjects. 18th CROI; 27 February - 4 March 2011; Boston, MA. Late breaker oral abstract 152LB.
与医生电话交流
网上免费问医生
看更多新文章>>
1.扫码下载好大夫App
2.在知识中添加您关注的疾病
3.添加成功后，最新的医生文章，每天推送给您。
发表于： 15:50
李在村大夫的信息
李在村大夫电话咨询
李在村大夫已经开通电话咨询服务直接与大夫本人通话，方便！快捷！
网上咨询李在村大夫
在此简单描述病情，向李在村大夫提问
李在村的咨询范围：
付费咨询要求：（ 女性患者请咨询其他相关专业医生）。艾滋病及恐艾咨询。
李在村主治疾病知识介绍
性病艾滋病临床诊疗中心好评科室
性病艾滋病临床诊疗中心分类问答}